-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Patients with type 2 diabetes often require multiple treatments to achieve and maintain satisfactory glycemic contr.
Background: Patients with type 2 diabetes often require multiple treatments to achieve and maintain satisfactory glycemic contr.
OBJECTIVE: Multiple studies support the efficacy of GLP-1RA combined with basal insulin in patients with type 2 diabetes who fail to respond to dual/triple oral thera.
Materials and methods: This study is based on a reported trial (LixiLan-G), a randomized, open-label, active-controlled, parallel-group, phase 3 26-week treatment study with iGlarLixi extending only one arm for 26 wee.
At baseline and week 26, participants underwent a standardized mixed meal test (MMTT) of approximately 600 kcal (50%-55% carbohydrate, 15%-20% protein and 25%-30% fat) Liquid formu.
Results: In the GLP-1RA group, both body weight and glycated hemoglobin decreased at 26 weeks, but there were no significant changes in insulin secretion/β-cell function paramete.
Table 1 Baseline metabolic parameters and their changes at follow-up
Figure 1 Glucose and C-peptide curves at baseline and 26 weeks for both grou.
Figure 1 Glucose and C-peptide curves at baseline and 26 weeks for both grou.
Figure 2 Insulin secretion-blood glucose dose-response curves of iGlarLixi and GLP-1RA groups at baseline and 26 wee.
Figure 2 Insulin secretion-blood glucose dose-response curves of iGlarLixi and GLP-1RA groups at baseline and 26 wee.
Figure 3 Multivariate logistic regression for the probability of HbA1c <48 mmol/mol (<5%) at Week 2 Delta glucose sensitivity is the change in glucose sensitivity between week 26 and baseli.
Figure 3 Multivariate logistic regression for the probability of HbA1c <48 mmol/mol (<5%) at Week 2 Delta glucose sensitivity is the change in glucose sensitivity between week 26 and baseli.
CONCLUSIONS: In patients with type 2 diabetes taking metformin, iGlarLixi for 26 weeks significantly improved beta-cell function while reducing endogenous insulin release and food absorpti.
Original source: Ferrannini E, Niemoeller E, Dex T, et .
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabet.
Diabetes Obes Metab 2022 06;24(6) Fixed -ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabet.
Leave a comment here
